Renoprotective Effects of DPP-4 Inhibitors.

摘要: Diabetic kidney disease (DKD) is the leading cause of end-stage renal (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in treatment patients with type 2 diabetes (T2D). DPP-4 reduce glucose levels by inhibiting degradation incretins. a ubiquitous protein exopeptidase activity that exists cell membrane-bound and soluble forms. It has been shown an increased associated development DKD. A series clinical experimental studies showed have beneficial effects on DKD, independent their glucose-lowering abilities, which mediated anti-fibrotic, anti-inflammatory, anti-oxidative stress properties. In this review article, we highlight current understanding efficacy mechanisms underlying renoprotection under diabetic conditions.